Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

BACKGROUND: The propagation of prions, the causative agents of Creutzfeldt-Jakob disease and other human prion diseases, requires post-translational conversion of normal cellular prion protein to disease-associated forms. The antimalarial drug quinacrine (mepacrine) prevents this conversion in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Collinge, John, Gorham, Michele, Hudson, Fleur, Kennedy, Angus, Keogh, Geraldine, Pal, Suvankar, Rossor, Martin, Rudge, Peter, Siddique, Durre, Spyer, Moira, Thomas, Dafydd, Walker, Sarah, Webb, Tom, Wroe, Steve, Darbyshire, Janet
Formato: Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2009
Materias:
Fast track — Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660392/
https://www.ncbi.nlm.nih.gov/pubmed/19278902
http://dx.doi.org/10.1016/S1474-4422(09)70049-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660392/
https://www.ncbi.nlm.nih.gov/pubmed/19278902
http://dx.doi.org/10.1016/S1474-4422(09)70049-3

Ejemplares similares